HYR-PB21: A Comprehensive Analysis of a Novel Bupivacaine Pamoate Cocrystal Formulation for Extended-Duration Postoperative Analgesia

Executive Summary

HYR-PB21 is an investigational, sustained-release formulation of the well-established local anesthetic bupivacaine, engineered specifically for the management of postoperative pain.[1] Developed by Hefei Cosource Pharmaceuticals, Inc., this novel therapeutic is currently in Phase 3 clinical trials in China for anesthesia and postoperative pain, positioning it as a significant new entrant in the non-opioid analgesics market.[2]

It is critical to establish at the outset that the vast majority of peer-reviewed literature, patent filings, and clinical trial registrations unequivocally identify HYR-PB21 as a bupivacaine formulation.[1] A single source describing a similarly named compound as a small-molecule kinase inhibitor for oncology is considered erroneous or referring to a separate, unrelated agent and is disregarded for the purposes of this analysis.[5]

The core innovation of HYR-PB21 lies in its unique pharmaceutical formulation: a bupivacaine pamoate cocrystal that forms a microparticle suspension for injection.[6] This molecular architecture confers very low solubility in aqueous environments, creating a depot effect at the site of administration that facilitates a slow, continuous release of bupivacaine over an extended period.[6] This mechanism contrasts with more complex delivery platforms, such as the liposomal technology used in market competitors.

Preclinical studies in established animal models have demonstrated a compelling efficacy profile, with HYR-PB21 providing a significantly longer duration of local anesthesia compared to both standard bupivacaine hydrochloride (HCl) and the leading extended-release competitor, liposomal bupivacaine.[3] This superior duration of action was subsequently validated in a pivotal multicenter, randomized controlled trial involving patients undergoing hemorrhoidectomy. In this study, a single 300 mg dose of HYR-PB21 provided statistically superior pain control for up to 72 hours and significantly reduced the need for rescue opioid medication compared to standard bupivacaine HCl, all while maintaining a comparable safety profile.[1]

Pharmacokinetic studies in animals further suggest a potential systemic safety advantage, as the slow-absorption profile of HYR-PB21 results in substantially lower peak plasma concentrations (Cmax​) of bupivacaine compared to other formulations, which may reduce the risk of systemic toxicity.[6] Confirmation of this profile in humans awaits the publication of data from a completed Phase 1 trial.

HYR-PB21 is strategically positioned to address the significant unmet clinical need for effective, long-lasting, non-opioid postoperative pain solutions. By potentially offering superior duration of analgesia, an improved systemic safety profile, and a simpler manufacturing process, it represents a promising next-generation advancement in local anesthetic technology.

Table 1: HYR-PB21 Drug Profile Summary

Attribute	Description
Drug Name	HYR-PB21; HYR-PB21-LA
Active Ingredient	Bupivacaine
Formulation Technology	Bupivacaine Pamoate Cocrystal; Microparticle Suspension for Injection
Mechanism of Action	Voltage-gated sodium channel blocker
Primary Indication	Postoperative Pain; Anesthesia
Lead Developer	Hefei Cosource Pharmaceuticals, Inc.
Highest Development Phase	Phase 3 (China)

I. Pharmaceutical Profile and Formulation Science

1.1 The Bupivacaine Pamoate Cocrystal: A Novel Molecular Architecture

The defining characteristic of HYR-PB21 is its formulation as a bupivacaine pamoate cocrystal, which is administered as a microparticle suspension injection.[6] This represents a sophisticated application of crystal engineering to modulate the pharmacokinetic properties of a known active pharmaceutical ingredient. It is a strategic departure from more common extended-release technologies that rely on complex carriers like liposomes or biodegradable polymers.[4]

Detailed structural analysis using single crystal X-ray diffraction has revealed that HYR-PB21-LA is not a simple salt but a highly organized "supermolecular complex".[6] This complex possesses a specific stoichiometry, comprising eight molecules of bupivacaine, four molecules of pamoic acid, and eight molecules of water.[6] This 8:4:8 ratio, which simplifies to a 2:1:2 molar ratio of bupivacaine to pamoic acid to water, forms the fundamental building block of the crystal lattice. The structural integrity of this complex is maintained by an intricate network of hydrogen bonds and hydrophobic interactions between the constituent molecules.[6]

Intellectual property filings provide further insight into this structure. European patent EP3486233NWB1, assigned to the drug's developers, protects an insoluble complex formed by mixing bupivacaine and pamoic acid in a molar ratio greater than 1:1 and less than or equal to 4:1, with a preferred ratio of 2:1 (n=2).[4] This patent data directly corroborates the 2:1 bupivacaine-to-pamoate ratio identified in the scientific literature. The patent also describes the existence of multiple distinct crystalline forms, or polymorphs (designated A, B, and C), of the bis(bupivacaine) pamoate complex. Each polymorph exhibits a unique X-ray powder diffraction (XRPD) pattern, indicating different arrangements of the molecules in the solid state.[4] The existence of these polymorphs underscores the complexity of the drug's solid-state chemistry and highlights the critical importance of precise manufacturing controls to ensure the consistent production of the desired crystalline form, which in turn dictates the drug's dissolution rate and clinical performance.

1.2 Physicochemical Properties and the Sustained-Release Principle

The entire therapeutic premise of HYR-PB21 is built upon a fundamental physicochemical property derived from its cocrystal structure: very low aqueous solubility. One analysis quantifies the solubility of HYR-PB21-LA in simulated body fluid as approximately 0.076 mg/mL.[7] This is a dramatic reduction compared to the solubility of standard bupivacaine HCl, which is on the order of 40 mg/mL.[6]

This low solubility is the engine of the sustained-release mechanism. When the microparticle suspension of HYR-PB21 is injected into tissue, the particles form a localized depot. Due to their poor solubility, these micron-sized crystals dissolve very slowly into the surrounding interstitial fluid, gradually liberating active bupivacaine molecules over a prolonged period.[6] This creates a stable, localized concentration of the anesthetic at the target nerve fibers for an extended duration. This mechanism is analogous to other long-acting injectable medications, such as the antipsychotic olanzapine pamoate monohydrate, which similarly uses a low-solubility pamoate salt to achieve a depot effect and slow drug release following intramuscular injection.[6] The formulation's elegance lies in its inherent simplicity; rather than encapsulating the drug in an external carrier, the drug's own solid-state form has been engineered to control its release, a strategy that may offer significant advantages in manufacturing, stability, and cost.

1.3 Intellectual Property and Development

The development of HYR-PB21 is led by Hefei Cosource Pharmaceutical Co., Ltd., a company based in Hefei, China, which is also referred to in some documents as Hefei Heyuan Pharmaceutical Co., Ltd.[3] The key inventors, including Shanchun Zhang, Yihua Wang, and Jiashi Peng, are listed on the primary patent protecting the technology.[4]

The patent filings explicitly articulate the strategic rationale behind the drug's development. The inventors sought to create a long-acting local anesthetic that could provide analgesia for at least three days while avoiding the complex production processes associated with liposomal formulations like the market competitor Exparel®.[4] This indicates a clear objective to develop a product with potential advantages in cost of goods and manufacturing scalability.

While the clinical development program is currently focused on the Chinese market, the company's commercial ambitions appear to be global. Patent applications for the bupivacaine pamoate complex have been filed in numerous major international jurisdictions, including the United States, Europe, Canada, Australia, Japan, and South Korea, signaling a long-term strategy for broader market access.[10]

II. Pharmacological Profile and Mechanism of Action

2.1 Primary Pharmacodynamics: Sodium Channel Blockade

As a formulation of bupivacaine, HYR-PB21 functions through the well-established mechanism of action of amino-amide local anesthetics.[11] The primary molecular target of bupivacaine is the voltage-gated sodium channel located on the intracellular side of the neuronal membrane.[11]

Nerve impulse transmission, including the signaling of pain, is dependent on the generation and propagation of action potentials. This process is initiated by a rapid influx of sodium ions (Na+) through these channels, leading to depolarization of the nerve membrane. Bupivacaine physically binds to the sodium channel, locking it in an inactivated state and thereby blocking the influx of sodium ions.[11] This inhibition prevents the nerve from reaching the threshold potential required for depolarization. Consequently, the initiation and conduction of pain signals from the periphery to the central nervous system are effectively halted in the anesthetized area.[13] This provides potent, localized, non-opioid analgesia.[13]

2.2 Pharmacokinetics: The Key Differentiator

While the pharmacodynamic mechanism of HYR-PB21 is identical to standard bupivacaine, its pharmacokinetic profile is fundamentally different and is the source of its therapeutic innovation.

2.2.1 Preclinical Animal Pharmacokinetics

A preclinical study in rats, which included a pharmacokinetic arm conducted concurrently with the tail-flick efficacy test, provides the most detailed available data on the systemic exposure of HYR-PB21.[6] The results highlight a significantly altered absorption profile compared to other formulations.

When compared to an equivalent dose of standard bupivacaine HCl (2.5 mg/mL), HYR-PB21-LA produced a mean peak plasma concentration (Cmax​) that was approximately 70% lower (123 ng/mL for HYR-PB21-LA versus 409 ng/mL for bupivacaine HCl).[6] An even more striking difference was observed in comparison to liposomal bupivacaine. At an equivalent dose of 5 mg/mL, HYR-PB21-LA resulted in a

Cmax​ of 191 ng/mL, which was less than half the 420 ng/mL peak observed with the liposomal formulation.[6]

Despite these dramatically lower peak concentrations, the total systemic drug exposure, as measured by the area under the concentration-time curve from time zero to infinity (AUC0−∞​), was found to be comparable between HYR-PB21-LA and its respective comparators at equivalent doses.[6] This combination of a blunted

Cmax​ and a similar AUC demonstrates that the formulation does not reduce the total amount of drug absorbed but rather slows the rate of absorption significantly. This "flattening" of the pharmacokinetic curve is the direct result of the slow dissolution of the cocrystal depot at the injection site and is the basis for both the extended duration of action and a potential systemic safety advantage.

2.2.2 Human Pharmacokinetics: A Critical Data Gap

At present, there is no publicly available human pharmacokinetic data for HYR-PB21.[1] This represents the most significant gap in the current understanding of the drug.

A crucial Phase 1, first-in-human (FTIH) clinical trial (NCT04169256) was specifically designed to address this question. The study's primary objectives were to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of HYR-PB21 administered subcutaneously to healthy volunteers.[15] The trial protocol included a comprehensive PK sampling schedule, with plasma bupivacaine concentrations measured at numerous time points up to 14 days (336 hours) post-dose, allowing for the precise determination of key parameters such as

Cmax​, time to peak concentration (Tmax​), AUC, and elimination half-life (t1/2​).[16]

Significantly, this study included an active comparator arm using EXPAREL (liposomal bupivacaine), which would have provided the first direct, head-to-head comparison of the human pharmacokinetic profiles of these two leading extended-release technologies.[16] According to the clinical trial registry, the study was completed in July 2020.[16] However, the results have not been posted or otherwise disseminated in the public domain.[16] The fact that the developer has advanced the drug into Phase 3 trials suggests that the Phase 1 results were favorable and met internal progression criteria. Nevertheless, until this data is made public, any claims about HYR-PB21's superior human safety profile based on a lower

Cmax​ remain a well-founded but unconfirmed extrapolation from preclinical findings.

III. Preclinical Efficacy and Safety Evaluation

3.1 Animal Models and Methodology

The preclinical efficacy of HYR-PB21 was rigorously evaluated in two standard and well-validated animal models of local anesthesia.[3] These studies were designed to provide robust proof-of-concept for the formulation's extended-release properties and to compare its performance directly against both the standard of care and a key commercial competitor.

The first model was the guinea pig intradermal weal/pin-prick assay. In this model, the test article is injected intradermally, and the degree of peripheral nociceptive blockade is assessed by measuring the inhibition of the cutaneous trunci muscle reflex (a skin twitch) in response to a standardized pin-prick stimulus.[3] The second model was the

rat tail-flick test, which evaluates nerve sensory blockade. Here, the drug is injected near the caudal nerve in the rat's tail, and efficacy is measured by the latency of the rat to "flick" its tail away from a thermal heat source.[3]

In both models, HYR-PB21-LA was tested against a vehicle control (placebo), standard bupivacaine HCl, and liposomal bupivacaine (EXPAREL), allowing for a comprehensive comparative assessment.[3]

3.2 Preclinical Efficacy Findings

The primary and most significant finding across all preclinical testing was the substantially prolonged duration of local anesthesia produced by HYR-PB21-LA.[3]

In the guinea pig pin-prick model, HYR-PB21-LA demonstrated a clear dose-dependent increase in the duration and magnitude of its anesthetic effect. When compared directly to an equivalent dose of liposomal bupivacaine (10 mg/mL), HYR-PB21-LA produced a significantly greater overall anesthetic effect, as measured by the area under the effect-time curve (AUEC), and had a significantly slower offset of action (p<0.0001).[3] The data showed that the duration of effective sensory blockade was more than doubled for HYR-PB21-LA compared to the liposomal formulation (mean duration of 690 minutes versus 330 minutes, respectively).[6]

The results from the rat tail-flick model were even more pronounced. A 2.5 mg/mL dose of HYR-PB21-LA maintained a significant anesthetic effect for 5 hours, a duration that was fivefold longer than that achieved with an equivalent dose of standard bupivacaine HCl.[3] In a head-to-head comparison with liposomal bupivacaine, a 5 mg/mL dose of HYR-PB21-LA sustained a significant anesthetic effect for 8 hours, whereas the effect of the equivalent dose of liposomal bupivacaine lasted for only 1 hour—a remarkable eightfold increase in the duration of action.[3]

Importantly, despite its greatly extended duration, the onset of action for HYR-PB21-LA was found to be rapid and comparable to both the highly soluble bupivacaine HCl and the liposomal formulation. In the guinea pig model, complete sensory blockade was observed at the first major assessment time point of 30 minutes for all bupivacaine-containing groups.[3] This finding is crucial, as it alleviates potential concerns that a low-solubility formulation might have a delayed onset, and confirms its suitability for providing immediate pain relief at the time of surgical closure.

Table 2: Comparative Efficacy in Preclinical Models

Model / Metric	HYR-PB21-LA Result	Liposomal Bupivacaine Result	Bupivacaine HCl Result
Guinea Pig Pin-Prick Duration of Inhibition (min) at 10 mg/mL	690	330	Not reported at this dose
Rat Tail-Flick Duration of Anesthesia (h) at 2.5 mg/mL	5	Not reported at this dose	1
Rat Tail-Flick Duration of Anesthesia (h) at 5 mg/mL	8	1	Not applicable

3.3 Local Tissue Tolerance and Safety

To assess the local safety of the novel formulation, histopathological examinations of the injection sites were conducted in both rats and guinea pigs 48 hours after drug administration.[6] The microscopic evaluation revealed findings of minimal to moderate monocytic inflammation in the tissues of animals treated with HYR-PB21-LA. This type of inflammatory response is consistent with an expected and generally well-tolerated local reaction to the presence of a foreign material, such as injected microparticles.[6]

Crucially, the incidence and severity of this local inflammation were comparable to those observed in the animals that received equivalent doses of liposomal bupivacaine.[6] This result provides strong preclinical evidence that the bupivacaine pamoate cocrystal formulation does not induce any new or more severe local tissue toxicity compared to the existing market-leading extended-release product, de-risking a key aspect of its safety profile ahead of human trials.

IV. Clinical Development and Efficacy in Postoperative Pain Management

4.1 Phase 1 First-in-Human Trial (NCT04169256)

The clinical development program for HYR-PB21 began with a Phase 1, first-in-human trial designed to establish its initial safety, tolerability, and pharmacokinetic/pharmacodynamic profile in humans.[15] The study was a single-center, randomized, double-blind, placebo-controlled, single ascending dose-escalation design conducted in 32 healthy adult volunteers in Australia.[16]

Participants were randomized to receive a single subcutaneous injection of HYR-PB21 at one of three escalating dose levels (100 mg, 200 mg, or 400 mg), an active comparator (200 mg of liposomal bupivacaine), or a placebo (normal saline).[16] The primary objectives were to assess safety and tolerability, while secondary objectives focused on characterizing the pharmacokinetic and pharmacodynamic profiles.[16] The trial was sponsored by Fruithy Medical Pty Ltd, an affiliate of Hefei Cosource, and was officially completed in July 2020.[16] As previously noted, the results of this foundational study have not yet been made public.

4.2 Pivotal Efficacy Trial in Hemorrhoidectomy (ChiCTR2000041318)

The most significant clinical evidence for HYR-PB21 to date comes from a multicenter, randomized, double-blind, positive-controlled trial conducted in China and published in the prestigious British Journal of Anaesthesia.[1] The study was strategically designed to evaluate the efficacy and safety of HYR-PB21 in a surgical model known for severe postoperative pain: hemorrhoidectomy.[1]

A total of 72 patients undergoing surgery for prolapsing hemorrhoids were enrolled and randomized into three groups. Following the surgical procedure, patients received a single local infiltration of either HYR-PB21 at a dose of 150 mg, HYR-PB21 at a dose of 300 mg, or an active control of 75 mg of standard bupivacaine HCl.[1]

The primary efficacy endpoint was the cumulative pain score, assessed using a numeric rating scale (NRS) at rest, over the first 72 hours after surgery.[1] The results were statistically significant and clinically meaningful. The high-dose (300 mg) HYR-PB21 group demonstrated a mean cumulative pain score of 87, which was nearly 50% lower than the mean score of 166 recorded in the bupivacaine HCl group (

P<0.001).[1] This result provides clear evidence of superior and sustained analgesia throughout the critical three-day postoperative period.

The study also demonstrated a powerful opioid-sparing effect, a key secondary endpoint and a major goal in modern perioperative care. There was a clear dose-response relationship, with both the 150 mg and 300 mg HYR-PB21 groups showing a reduction in the total amount of rescue opioid medication consumed and a lower proportion of patients requiring any rescue opioids at all, compared to the bupivacaine HCl reference group.[1] These findings confirm that the superior local analgesia provided by HYR-PB21 translates directly into a reduced reliance on systemic opioids.

Table 3: Summary of Phase 2/3 Hemorrhoidectomy Trial (ChiCTR2000041318)

Outcome Measure	300 mg HYR-PB21 Group	150 mg HYR-PB21 Group	75 mg Bupivacaine HCl Group	Statistical Significance
Cumulative Pain Score at 72h	87	Not specified	166	P<0.001 (300 mg vs HCl)
Total Opioid Use	Dose-dependent reduction	Dose-dependent reduction	Reference	Not specified
Proportion Requiring Opioids	Dose-dependent reduction	Dose-dependent reduction	Reference	Not specified

4.3 Overall Development Status and Pipeline

Following the successful outcomes of the hemorrhoidectomy trial, the development of HYR-PB21 has progressed to Phase 3 in China.[2] The indications being pursued in this advanced stage are

Anesthesia and Postoperative Pain, reflecting the broad potential applicability of the drug across various surgical settings.[2] Earlier-stage (Phase 1) investigations were also initiated in China for other pain-related indications, including general analgesia and postherpetic neuralgia, suggesting that the developer may explore expanding the drug's label into chronic pain conditions in the future.[2]

V. Safety and Tolerability Profile

5.1 Foundational Safety Profile of Bupivacaine

The safety profile of HYR-PB21 must be understood within the context of its active moiety, bupivacaine. The primary safety risks associated with bupivacaine are not related to local effects but to systemic toxicity resulting from excessive absorption into the bloodstream. This toxicity is dose- and concentration-dependent and primarily affects the central nervous and cardiovascular systems.[11]

Central Nervous System (CNS) Toxicity: This is typically the first sign of systemic toxicity and occurs at lower plasma concentrations than cardiotoxicity. Early symptoms include circumoral numbness, tingling, tinnitus, restlessness, anxiety, and dizziness. If plasma levels continue to rise, these symptoms can progress to more severe events, including muscle twitching, tremors, seizures, and ultimately, coma and respiratory arrest.[11]

Cardiovascular (CV) Toxicity: Bupivacaine is known to be more cardiotoxic than other commonly used local anesthetics.[12] High systemic concentrations can depress cardiac conduction and excitability, leading to severe adverse events such as hypotension, arrhythmias (including ventricular arrhythmias), bradycardia, heart block, and cardiac arrest.[11] This risk is particularly pronounced with accidental intravascular injection. The 0.75% concentration of bupivacaine carries a U.S. FDA boxed warning regarding the risk of cardiac arrest, particularly in the setting of obstetrical epidural anesthesia, for which its use is not recommended.[25]

Contraindications for bupivacaine include known hypersensitivity to amide-type local anesthetics and its use in obstetrical paracervical block anesthesia, which has been associated with fetal bradycardia and death.[23]

5.2 Clinical Safety Data for HYR-PB21

Safety and tolerability were key secondary endpoints in the pivotal hemorrhoidectomy trial.[1] The study's conclusion on this matter was definitive: the groups treated with HYR-PB21, at both the 150 mg and 300 mg doses, "did not show more adverse effects than the bupivacaine HCl group".[1]

This is a critically important finding. It demonstrates that, within the context of this trial, the novel bupivacaine pamoate cocrystal formulation was as well-tolerated as the standard, widely used formulation of the drug. This suggests that the new excipient (pamoic acid) and the unique crystalline structure do not introduce any new or unexpected local or systemic safety signals. Achieving superior efficacy with a comparable safety profile is a primary goal in the development of new formulations, and this trial provides strong evidence that HYR-PB21 meets this objective. However, this conclusion is based on a single trial in a specific surgical population, and a broader safety database will need to be established in the ongoing Phase 3 program to support regulatory approval for wider use.

5.3 Projected Safety Advantages Based on Pharmacokinetics

A central hypothesis for HYR-PB21 is that its unique pharmacokinetic profile may confer a significant systemic safety advantage over existing bupivacaine formulations. This hypothesis is directly rooted in the preclinical PK data, which demonstrated a substantially lower peak plasma concentration (Cmax​) for HYR-PB21 compared to both bupivacaine HCl and liposomal bupivacaine.[6]

Since bupivacaine's systemic toxicity is directly correlated with its peak plasma concentration, a formulation that can achieve therapeutic efficacy while maintaining a lower Cmax​ inherently possesses a wider therapeutic window.[11] By slowing the rate of absorption from the injection site, HYR-PB21 may reduce the risk of plasma concentrations reaching the thresholds associated with CNS or CV toxicity. This could be particularly advantageous in procedures requiring large volumes of local anesthetic or in patient populations more susceptible to systemic effects. While this projected safety benefit is a compelling component of the drug's value proposition, it remains theoretical until confirmed by the publication of the human pharmacokinetic data from the completed Phase 1 trial (NCT04169256).

VI. Strategic Analysis and Market Positioning

6.1 The Unmet Need in Postoperative Pain

Effective management of postoperative pain remains a major challenge in modern medicine. Inadequately controlled pain is associated with delayed patient recovery, prolonged hospital stays, increased risk of complications, and substantial healthcare costs.[6] For decades, the mainstay of treatment for moderate-to-severe postoperative pain has been systemic opioid analgesics. However, the use of opioids is fraught with a wide range of debilitating side effects, including nausea, vomiting, constipation, sedation, and respiratory depression. Furthermore, the widespread use of opioids in the postoperative setting has been identified as a significant contributor to the ongoing opioid crisis, as it can lead to long-term dependence and addiction.[1]

This clinical landscape has created a pressing and universally recognized unmet need for effective, long-lasting, non-opioid or opioid-sparing analgesic strategies. Local anesthetics are an ideal solution in principle, but standard formulations like bupivacaine HCl have a duration of action (typically less than 8 hours) that is mismatched with the clinical course of postoperative pain, which frequently persists for 72 hours or more.[3] This gap has driven the development of extended-release local anesthetic formulations designed to bridge this therapeutic window.

6.2 Competitive Landscape of Extended-Release Local Anesthetics

HYR-PB21 is entering a competitive but growing market for long-acting local anesthetics. Several technologies have been developed to address this need, each with a distinct profile.

Table 4: Competitive Landscape of Extended-Release Bupivacaine Formulations

Product Name	Technology	Approved Duration of Action	Key Approved Indications (U.S. FDA)	Developer
HYR-PB21	Bupivacaine Pamoate Cocrystal	>72 hours (Projected)	Postoperative Pain (Phase 3 in China)	Hefei Cosource Pharmaceuticals
EXPAREL®	Liposomal Bupivacaine (DepoFoam®)	Up to 72 hours	Surgical site infiltration; interscalene brachial plexus block	Pacira Biosciences
ZYNRELEF®	Bupivacaine/Meloxicam Polymer Solution	Up to 72 hours	Soft tissue and orthopedic surgical procedures	Heron Therapeutics
XARACOLL®	Bupivacaine HCl Collagen Implant	Up to 24 hours	Open inguinal hernia repair	Innocoll Pharmaceuticals
POSIMIR®	Bupivacaine Solution (SABER®)	Up to 72 hours	Arthroscopic subacromial decompression	DURECT Corporation

The primary competitor and market leader is EXPAREL® (liposomal bupivacaine), which utilizes a multivesicular liposome technology (DepoFoam®) to provide analgesia for up to 72 hours.[8] It serves as the main benchmark against which new entrants are measured. Other competitors include

ZYNRELEF®, which combines bupivacaine with the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a polymer-based solution to provide analgesia for up to 72 hours [28], and solid-dose formulations like

XARACOLL®, a bioresorbable collagen implant providing up to 24 hours of relief.[31]

6.3 HYR-PB21's Potential Competitive Advantages

HYR-PB21 is positioned not as a "me-too" product but as a potential next-generation technology with several key points of differentiation that could allow it to capture significant market share.

1. Potentially Superior Duration of Action: The most compelling potential advantage is duration. Preclinical data suggests that HYR-PB21 may last significantly longer than its competitors, with studies showing an eightfold longer duration of anesthesia than liposomal bupivacaine in the rat tail-flick model.[6] If this translates to human clinical practice, it could provide effective pain control well beyond the standard 72-hour window, covering the entire initial recovery period for many surgeries and further reducing the need for any opioid rescue.
2. Formulation and Manufacturing Simplicity: The development of HYR-PB21 was explicitly motivated by a desire to avoid the manufacturing complexity of liposomal formulations.[4] A cocrystal suspension is a more conventional pharmaceutical dosage form that is likely simpler, more stable, and more cost-effective to produce at scale. This could translate into a lower cost of goods, allowing for more competitive pricing and wider adoption.
3. Potential Systemic Safety Advantage: As detailed previously, the unique pharmacokinetic profile of HYR-PB21, characterized by a blunted Cmax​, may offer a superior systemic safety profile by reducing the risk of dose-related toxicity.[6] This could be a significant differentiating factor for clinicians, especially in high-risk patients or procedures requiring large volumes of anesthetic.

The initial development strategy appears focused on securing approval and generating revenue in the large Chinese market, a logical approach for its China-based developer.[2] However, the extensive international patent filings and the decision to conduct the Phase 1 trial in Australia clearly indicate a long-term global strategy, likely involving partnerships for commercialization in the U.S. and European markets after establishing robust proof-of-concept in China.[10]

VII. Conclusions and Future Outlook

7.1 Summary of Evidence

HYR-PB21 is a technologically distinct and highly promising investigational therapeutic for postoperative pain. Its formulation as a bupivacaine pamoate cocrystal represents an innovative and elegant application of pharmaceutical science to address a clear clinical need. The available evidence from preclinical and clinical studies provides a strong and consistent narrative:

• Superior Efficacy: HYR-PB21 has demonstrated the ability to provide a significantly longer duration of local analgesia than both standard bupivacaine and the market-leading liposomal formulation in animal models. This superiority was confirmed in a pivotal human trial, where it led to a nearly 50% reduction in the total pain burden over 72 hours compared to bupivacaine HCl.
• Opioid-Sparing: The enhanced local analgesia translates directly into a clinically meaningful reduction in the need for systemic opioid medications, a critical benefit in the current healthcare environment.
• Favorable Safety Profile: The formulation has been shown to be well-tolerated, with a safety profile comparable to standard bupivacaine HCl in clinical use and local tissue tolerance similar to liposomal bupivacaine in preclinical models.
• Potential for Enhanced Systemic Safety: The unique pharmacokinetic profile, characterized by a low peak plasma concentration, suggests a potential for an improved systemic safety window, though this requires confirmation with human data.

7.2 Critical Data Gaps and Unanswered Questions

Despite the overwhelmingly positive data, several critical questions remain that must be answered to fully assess the potential of HYR-PB21.

1. Human Pharmacokinetics: The most significant outstanding issue is the absence of published human pharmacokinetic data from the completed Phase 1 trial (NCT04169256). This data is essential to confirm that the favorable low-Cmax​ profile observed in animals translates to humans, which is the foundation of the drug's projected systemic safety advantage.
2. Phase 3 Trial Results: The outcomes of the ongoing Phase 3 trials in China are paramount. These studies must replicate the efficacy and safety findings from the hemorrhoidectomy trial across a broader range of surgical procedures and diverse patient populations to support a comprehensive regulatory submission and widespread clinical adoption.
3. Global Regulatory Strategy: The developer's specific plans and timelines for engaging with regulatory agencies outside of China, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are not yet clear.

7.3 Expert Outlook

HYR-PB21 stands out as a formidable candidate in the non-opioid postoperative pain market. Its cocrystal technology is scientifically sound and appears to confer tangible advantages in both efficacy and formulation simplicity. If the robust preclinical and Phase 2 data are confirmed in the ongoing Phase 3 program, and if the human pharmacokinetic data validates the projected safety benefits, HYR-PB21 has the potential to become a best-in-class agent for extended-duration local anesthesia.

The key milestones to monitor in the near term are the public release of the Phase 1 pharmacokinetic data and the announcement of top-line results from the Phase 3 clinical trials. Positive outcomes from these events would significantly de-risk the program and likely catalyze substantial interest from potential international commercialization partners. In conclusion, HYR-PB21 is a well-designed drug candidate with a strong scientific rationale and compelling clinical data that positions it to make a significant impact on the management of postoperative pain.

Works cited

1. Local infiltration of HYR-PB21, a sustained-release formulation of bupivacaine, provides analgesia and reduces opioid requirement after haemorrhoidectomy: a randomised controlled trial - ResearchGate, accessed August 26, 2025, https://www.researchgate.net/publication/364363985_Local_infiltration_of_HYR-PB21_a_sustained-release_formulation_of_bupivacaine_provides_analgesia_and_reduces_opioid_requirement_after_haemorrhoidectomy_a_randomised_controlled_trial
2. HYR-PB21 - Drug Targets, Indications, Patents - Synapse, accessed August 26, 2025, https://synapse.patsnap.com/drug/e7172b11ecdb4a828d2234a13cd7d22d
3. HYR-PB21-LA, a potential extended-release bupivacaine formulation, produces long-lasting local anesthesia in rats and guinea pigs - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/32170037/
4. POORLY SOLUBLE COMPLEX OR SOLVATE THEREOF, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF - Patent 3486233, accessed August 26, 2025, https://data.epo.org/publication-server/rest/v1.0/publication-dates/20210127/patents/EP3486233NWB1/document.html
5. What is HYR-PB21 used for? - Patsnap Synapse, accessed August 26, 2025, https://synapse.patsnap.com/article/what-is-hyr-pb21-used-for
6. HYR-PB21-LA, a potential extended-release bupivacaine ..., accessed August 26, 2025, https://rapm.bmj.com/content/45/5/367
7. SUSTAINED-RELEASE PREPARATION COMPOSITION - European Patent Office - EP 4279065 A1 - Googleapis.com, accessed August 26, 2025, https://patentimages.storage.googleapis.com/ac/70/41/fca5c5f7e7fe08/EP4279065A1.pdf
8. New formulations of bupivacaine for the treatment of postoperative pain: Liposomal bupivacaine and SABER-Bupivacaine - ResearchGate, accessed August 26, 2025, https://www.researchgate.net/publication/263708509_New_formulations_of_bupivacaine_for_the_treatment_of_postoperative_pain_Liposomal_bupivacaine_and_SABER-Bupivacaine
9. Local infiltration of HYR-PB21, a sustained-release formulation of bupivacaine, provides analgesia and reduces opioid requirement after haemorrhoidectomy: a randomised controlled trial - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/36243580/
10. WO2022152232A1 - Sustained-release preparation composition ..., accessed August 26, 2025, https://patents.google.com/patent/WO2022152232A1/en
11. Bupivacaine - Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/Bupivacaine
12. Bupivacaine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB00297
13. The effect of bupivacaine on analgesia and safety in patients undergoing hemorrhoidectomy: a meta-analysis - Frontiers, accessed August 26, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1331965/pdf
14. The effect of bupivacaine on analgesia and safety in patients undergoing hemorrhoidectomy: a meta-analysis - Frontiers, accessed August 26, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1331965/full
15. ANZCTR search results | Australian Clinical Trials, accessed August 26, 2025, https://www.australianclinicaltrials.gov.au/anzctr-search-results?condition_category=all&condition_code=allðics_approval=all&gender=all&healthy_volunteers=all&phase=all&purpose_of_study=all&recruitment_sites=NSW&recruitment_status=all&search_text=&page=846
16. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of HYR-PB21 in Healthy Volunteers - ClinicalTrials.gov, accessed August 26, 2025, https://clinicaltrials.gov/study/NCT04169256?tab=history&a=3
17. Study Details | Safety, Tolerability, Pharmacokinetic and, accessed August 26, 2025, https://clinicaltrials.gov/study/NCT04169256
18. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT04169256?tab=results
19. [PDF] Time to Analgesia Onset and Pharmacokinetics After Separate, accessed August 26, 2025, https://www.semanticscholar.org/paper/Time-to-Analgesia-Onset-and-Pharmacokinetics-After-Gadsden-Long/8b136e84d3c04f456cc1a43840cf9d957245c2dd
20. Fruithy Medical Pty Ltd - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed August 26, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/e0ee29c2d66d7fdeaa00879e894eac13
21. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of HYR-PB21 in Healthy Volunteers - ClinicalTrials.gov, accessed August 26, 2025, https://clinicaltrials.gov/study/NCT04169256?tab=history&a=1
22. HYR-PB21 offers effective analgesia and lowers need for opioids after hemorrhoidectomy, accessed August 26, 2025, https://www.medznat.ru/index.php/en/news/medical-news/hyr-pb21-offers-effective-analgesia-and-lowers-nee
23. Hydrochloride Injection, USP Bupivacaine Hydrochloride and Epinephrine Injection, USP Rx only - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018053s060lbl.pdf
24. Bupivacaine Uses, Side Effects & Warnings - Drugs.com, accessed August 26, 2025, https://www.drugs.com/mtm/bupivacaine.html
25. highlights of prescribing information - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018053s061lbl.pdf
26. risk of cardiac arrest with use of bupivacaine hydrochloride injection in obstetrical anesthesia - Pfizer, accessed August 26, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=4704
27. Bupivacaine: Package Insert / Prescribing Information - Drugs.com, accessed August 26, 2025, https://www.drugs.com/pro/bupivacaine.html
28. Extended Release of Bupivacaine from Temperature-Responsive PNDJ Hydrogels Improves Postoperative Weight-Bearing in Rabbits Following Knee Surgery - MDPI, accessed August 26, 2025, https://www.mdpi.com/1424-8247/17/7/879
29. bupivacaine - Drug Central, accessed August 26, 2025, https://drugcentral.org/drugcard/432
30. zynrelef - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s000lbl.pdf
31. A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a bupivacaine hydrochloride implant in patients undergoing abdominoplasty | Regional Anesthesia & Pain Medicine, accessed August 26, 2025, https://rapm.bmj.com/content/48/12/601